News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

May 29, 2020

XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis

XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan
May 27, 2020

FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients
May 20, 2020

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat

Submission for the treatment of anemia in adult patients with chronic kidney disease
Apr 30, 2020

Astellas Pharma Support Solutions Help to Address Evolving Patient Needs During COVID-19
Apr 9, 2020

Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review in China by the National Medical Products Administration
Feb 19, 2020

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer

- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -
Feb 11, 2020

XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC
Feb 10, 2020

Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treatment for Advanced Bladder Cancer

- After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination - - Findings To Be Presented During an Oral Session at the 2020 Genitourinary Cancers Symposium -
Feb 10, 2020

Astellas Global Health Foundation and AMPATH Announce a Three-Year $1.35 Million Grant to Aid Mental Health Programming in Western Kenya

- New Funding will Address Disparities in Mental Health Diagnosis and Treatment for 400,000 People in Need -
- Photos 1
Jan 29, 2020

Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products